60 Degrees Pharmaceuticals, Inc. Warrant financials
$0.0324+28.26%
Close Sep 25, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $1.4M | $681.3K | $253.6K |
| Gross profit | $627.4K | $296.6K | -$221.0K |
| Gross margin | 44.5% | 43.5% | −87.1% |
| Operating income | -$7.8M | -$9.7M | -$5.2M |
| Net income | -$7.9M | -$8.4M | -$3.9M |
| Net margin | −557.7% | −1237.3% | −1547.7% |
| Diluted EPS | $-11.73 | $-74.17 | $-236.72 |
| EBITDA | -$7.5M | -$6.1M | -$5.1M |
| Operating cash flow | -$6.8M | -$5.6M | -$4.5M |
| Free cash flow | -$7.0M | -$5.8M | -$4.6M |
| Diluted shares | 0.7M | 0.1M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $1.5M | $1.7M | $2.1M |
| Short-term investments | $1.2M | $1.7M | $0.00 |
| Total debt | $144.0K | $155.9K | $0.00 |
| Total assets | $5.4M | $5.8M | $7.8M |
| Total liabilities | $2.0M | $1.8M | $3.0M |
| Shareholders' equity | $3.4M | $4.0M | $4.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology